Jan. 23 at 2:22 PM
Attached is a schedule of historical commercial-stage oncology focused M&A by year & month since 1/1/2017. Over the last 3 fiscal years, there have been, on average, 5 such M&A transactions per year or very roughly 1 every 2 months. Sometimes these transactions are concentrated in a short period & sometimes not.
It's now been almost 4 months since
$GMAB announced they were acquiring Merus. Using the last 3 years as a basis, we are overdue. Using last year, when there was a 6 month window between GTHX's exit & CKPT, we may not see one for another few months.
If anyone has any input on the next M&A candidate & why, we'd genuinely love to hear it.
Our guess of the next candidates (in order):
$URGN
$DAWN (only because of DAWN's trading profile...why DAWN's CEO invested
$100MM to buy an asset like MRSN that, per the acquiree's management, would only produce
$200MM in peak sales if ever approved, is a head scratcher)
$SNDX they appear to want to wait
$DCTH
This is not investment advice.
